Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $215.00 at BTIG Research

Palvella Therapeutics (NASDAQ:PVLA) had its price target upped by BTIG Research from $192.00 to $215.00 in a research note issued to investors on Wednesday,Benzinga reports. BTIG Research currently has a buy rating on the stock.

PVLA has been the topic of a number of other research reports. Canaccord Genuity Group boosted their target price on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Oppenheimer reissued an “outperform” rating and set a $200.00 price target on shares of Palvella Therapeutics in a research report on Monday, December 15th. TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. HC Wainwright upped their price objective on shares of Palvella Therapeutics from $200.00 to $255.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $193.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Palvella Therapeutics has an average rating of “Buy” and a consensus target price of $176.44.

Palvella Therapeutics Stock Up 6.8%

NASDAQ PVLA opened at $128.60 on Wednesday. The firm has a market capitalization of $1.52 billion, a PE ratio of -48.90 and a beta of -0.16. The stock’s 50 day moving average is $92.78 and its 200 day moving average is $78.86. Palvella Therapeutics has a twelve month low of $18.23 and a twelve month high of $129.32.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors have recently made changes to their positions in the company. Archer Investment Corp bought a new stake in shares of Palvella Therapeutics during the third quarter valued at approximately $28,000. Group One Trading LLC boosted its stake in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Palvella Therapeutics in the 3rd quarter worth $36,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Palvella Therapeutics in the second quarter worth $37,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares in the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Key Stories Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Phase 3 SELVA topline results show strong efficacy and tolerability for QTORIN™ 3.9% rapamycin in microcystic lymphatic malformations; company plans an NDA submission in H2 2026 — a potential first-ever FDA‑approved therapy for this rare condition. Phase 3 SELVA Results
• Positive Sentiment: Several sell‑side firms raised price targets and reiterated buy/outperform ratings after the Phase 3 readout (examples include Mizuho, BTIG and Chardan), which supports upside expectations and likely boosted buying interest. Analyst Coverage
• Neutral Sentiment: Palvella priced an upsized public offering of 1.6M shares at $125 per share to raise roughly $200M (plus a 30‑day option for 240k additional shares). Proceeds intended for QTORIN program development and general corporate purposes — this improves cash runway but increases share supply. Offering Pricing
• Negative Sentiment: Short interest rose ~22% in February to ~1.67M shares (~17.8% of float) with a ~5.5 days-to-cover ratio — elevated short positions can amplify volatility and create short-covering spikes or pressure depending on flow. (internal short‑interest report)
• Negative Sentiment: Insider activity shows recent sales (no insider buys reported in past 6 months), which some investors view as a negative signal on timing of share sales around the rally. (internal insider activity data)

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.